StreetAlpha.app
Home › Stocks › INBX

Inhibrx Biosciences, Inc. (INBX)

Healthcare
Members
LATEST PRICE

Inhibrx Biosciences develops cancer treatments built from engineered proteins, now in clinical trials. INBX reports earnings on Fri, Nov 13, 2026. In the past 30 days there were 1 dark pool print.

Prices, price targets and earnings estimates for INBX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is INBX in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 13
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated INBX in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for INBXThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
HC Wainwright & Co.Initiated
Aug 24Buy
StifelInitiated
Apr 8Buy
DateFirmActionRatingPrice target
Aug 24HC Wainwright & Co.InitiatedBuy
Apr 8StifelInitiatedBuy
Loading…

Whale Options Flow

90D

No whale options trades in INBX in the last 90 days.

Loading…

Dark Pool

30D
Prints
1
Notional
Members
Largest print
Members
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INBX is in one of them and how their past INBX trades turned out.

See how it works→ View all auto pilots→
INBX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INBX in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Inhibrx Biosciences

Inhibrx Biosciences is a biopharmaceutical company based in La Jolla, California. It develops biologic drug candidates, which are medicines made from proteins, using its own protein engineering platforms. Its candidates are being tested in clinical trials for cancers, including sarcomas, colorectal cancer, lung cancer and head and neck cancer. The company aims to offer these treatments to patients with serious diseases, if they are approved.

Headquarters
La Jolla, CA
Summary based on the company’s 2026 annual report (10-K) ↗